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Abstract
Type 2 diabetes mellitus is associated with accelerated cognitive decline. The underlying pathophysiological mechanisms still remain
to be elucidated although it is known that insulin signaling modulates neurotransmitter activity, including inhibitory g-aminobutyric
acid (GABA) and excitatory glutamate (Glu) receptors. Therefore, we examined whether levels of GABA and Glu are related to
diabetes status and cognitive performance.
Forty-one participants with type 2 diabetes and 39 participants without type 2 diabetes underwent detailed cognitive assessments
and 3-Tesla proton MR spectroscopy. The associations of neurotransmitters with type 2 diabetes and cognitive performance were
examined using multivariate regression analyses controlling for age, sex, education, BMI, and percentage gray/white matter ratio in
spectroscopic voxel.
Analysis revealed higher GABA+ levels in participants with type 2 diabetes, in participants with higher fasting blood glucose levels
and in participants with higher HbA1c levels, and higher GABA+ levels in participants with both high HbA1c levels and less cognitive
performance.
To conclude, participants with type 2 diabetes have alterations in the GABAergic neurotransmitter system, which are related to
lower cognitive functioning, and hint at the involvement of an underlying metabolic mechanism.
Abbreviations: 1H-MRS = proton magnetic resonance spectroscopy, CNS = central nervous system, Cr = creatine, CSF =
cerebrospinal ﬂuid, GABA = g-aminobutyric acid, Gln = glutamine, Glu = glutamate, Glx = combined Glu and Gln signals, GM = gray
matter, GPC = glycerophosphocholine, MEGA-PRESS = Mescher-Garwood-point resolved spectroscopy sequence, mI = myo-
inositol, MMSE = mini-mental state examination, NAA = n-acetyl aspartate, NAAG = n-acetylaspartylglutamate, PCh =
phosphocholine, tCho = total choline, tCr = total creatine, tNAA = total n-acetyl aspartate, WM = white matter.
Keywords: g-aminobutyric acid, cognition, glutamate, magnetic resonance spectroscopy, type 2 diabetes mellitusEditor: Xiwen Cheng.
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11. Introduction
Type 2 diabetes mellitus is an endocrine disorder characterized by
attenuated insulin signaling and decreased cellular responsiveness
to insulin. Since systemic insulin resistance is accompanied by
central insulin resistance, the complications of diabetes not only
involve peripheral tissues, but also the central nervous system
(CNS).[1,2] Indeed, type 2 diabetes is associated with cognitive
deﬁcits,[3] accelerated cognitive decline,[4] and an increased risk
for developing dementia and Alzheimer disease.[4–7] Insulin
signaling plays an important role in synaptic plasticity by
modulating neurotransmitter channel activity, including excit-
atory, and inhibitory receptors such as g-aminobutyric acid
(GABA) and glutamate (Glu) receptors.[8,9] Therefore, defects in
brain insulin signaling may give rise to neuronal dysfunction and
impaired cognitive performance.[10,11]
Proton MR spectroscopy (1H-MRS) provides the unique
opportunity to assess noninvasively the concentrations of neuro-
metabolites including neurotransmitters GABA and Glu in vivo,
through the identiﬁcation and quantiﬁcation of spectral peaks.
GABA is the major inhibitory neurotransmitter, whereas Glu is
the major excitatory neurotransmitter. At clinical ﬁeld strengths
(3.0T),GABAandGlu are difﬁcult to quantify due to the spectral
overlap with the signals of other metabolites, including n-acetyl
aspartate (NAA), total creatine (tCr), and glutamine (Gln).
However, advanced spectral editingmethods have been developed
that enable the detection of metabolites with strong spectral
overlap. For example, the MEscher-GArwood-point resolved
1
Table 1
Characteristics of the two cognition groups
∗
.
Low cognitive
function (n=39)
High cognitive
function (n=41) P value
Type 2 diabetes (%, n) 53.8 (n=21) 48.8 (n=20) 0.650†
Age, y 61.1±9.7 62.7±6.6 0.369
Sex (male, %, n) 56.4 (n=22) 56.1 (n=23) 0.978†
Education 0.889†
Low (%, n) 15.4 (n=6) 19.5 (n=8)
Middle (%, n) 46.2 (n=18) 43.9 (n=18)
High (%, n) 38.5 (n=15) 36.6 (n=15)
Verbal memory 37.1±10.1 49.6±9.1 <0.001
Executive function, s 63.3±35.6 34.7±12.6 <0.001
Verbal ﬂuency 20.3±4.9 27.6±5.7 <0.001
Cumulative cognition score 2.31±2.20 2.12±1.28 <0.001
Data are mean± standard deviation.
∗
Only participants who were included in the ﬁnal analysis; independent samples t test.
van Bussel et al. Medicine (2016) 95:36 Medicinespectroscopy sequence (MEGA-PRESS) edited H-MRS method
can be used for the quantiﬁcation of GABA.[12]
As 1H-MRS facilitates the assessment of neurotransmitters
GABA and Glu, it is a suitable technique to explore whether an
altered neurotransmitter metabolism underlies cognitive prob-
lems in type 2 diabetes. A previous 1H-MRS study with respect to
neurotransmitters in depressed type 2 diabetes has reported
decreased Glu levels[13] compared with healthy controls.
Moreover, lower GABA levels were observed in patients with
diabetic neuropathy.[14]
To our knowledge, no studies explored the neurotransmitter
metabolism of impaired cognitive performance in type 2 diabetes.
Therefore, the current study was designed to assess whether
neurotransmitters (GABA and Glu) are related to type 2 diabetes
status, cognitive performance, and the potential interaction
between type 2 diabetes and cognitive performance.† Pearson x2 test.2. Materials and methods
2.1. Study population
Forty-seven participants with type 2 diabetes and 41 participants
without type 2 diabetes were recruited from the ﬁrst 866
participants of the Maastricht Study for additional brain MRI
measurements. The Maastricht Study is an ongoing observation-
al, prospective, population-based cohort study that focuses on
the etiology, pathophysiology, complications, and comorbidities
of type 2 diabetes. Participants are between 40 and 75 years of
age and live in the southern part of the Netherlands.[15]
Participants are considered to have diabetes according to the
WHO2006 criteria if they use diabetes medication or if they have
a fasting blood glucose ≥7.0mmol/L or a 2-hours blood glucose
≥11.1mmol/L. Participants without type 2 diabetes are charac-
terized by fasting blood glucose<6.1mmol/L and a 2-hours
blood glucose <7.8mmol/L. At baseline inclusion, participants
underwent an extensive battery of measurements, including
cognitive performance tasks, blood pressure measurements, and
blood sampling. A detailed overview is provided in Schram
et al.[15] After their baseline measurements of the Maastricht
Study, participants were invited to participate in this MRI study.
Participants with the highest and lowest cognitive scores were
selected from the ﬁrst 866 participants to increase the probability
of ﬁnding MRI differences associated with cognitive decrements
(Table 1). A detailed selection procedure is provided in van Bussel
et al.[16] In brief, the division of participants in a low and high
cognition group was based on a cumulative score of three
neuropsychological tests covering the domains of verbal memory,
attention and ﬂexibility, and executive functioning (Table 1).
For matching, the scores for each neuropsychological test were
adjusted for age, sex, and education level by linear regression and
the cumulative cognition score was calculated by adding the
corresponding z-scores (standardized residuals) of the three
neuropsychological tests. Exclusion criteria for participants were:
a known history of stroke or neurological disease, if the time
span between enrollment in the Maastricht Study and MRI was
>1.5 years, incomplete cognitive assessments, type 1 diabetes
mellitus, mild cognitive impairment, participants with the
metabolic syndrome, participants with color blindness, partic-
ipants with an unknown diabetes status, and for participants
without type 2 diabetes, an impaired fasting blood glucose level.
The low and high cognition groups were matched on age, sex,
and education level, and display a similar distribution of
participants with and without type 2 diabetes (Table 1).2After taking into account those who declined the invitation and
exclusion of participants with MRI contra-indications, a total of
47 and 41 participants with and without type 2 diabetes were
included, respectively.
Prior to MRI, all participants underwent a general cognitive
function test (Mini-Mental State Examination, MMSE[17]) to
assess clinically signiﬁcant differences in cognitive performance
compared with the baseline cognitive tests at enrollment in the
Maastricht Study. None of the participants were excluded based
on aMMSE score of24. Structural brain andMR spectroscopy
scans were obtained from all participants. This study was
approved by the Medical Ethics Committee of the Maastricht
University Medical Center (MUMC+), the Netherlands, and
all participants gave written informed consent. The study
is registered at http://www.clinicaltrials.gov with identiﬁer
NCT01705210.2.2. Magnetic resonance imaging
MRI data were acquired on a 3T scanner (Achieva TX, Philips
Healthcare, Best, The Netherlands) using a 32-element head coil
for parallel imaging. The MRI protocol consisted of structural
scans for neuroradiological evaluation (including T1-, T2-, T2∗-
weighted, and ﬂuid attenuated inversion recovery (FLAIR)
sequences) and 1H-MRS scans. A 3-dimensional T1-weigthed
(T1) fast ﬁeld echo sequence (TR/TE 8.1/3.7 ms, 1.00mm
isotropic voxel size, 170 continuous slices, matrix size of 240 
240, and 7:56 minutes acquisition time) was acquired and used
for the positioning of the spectroscopic voxel and voxel
segmentation. 1H-MRS were acquired from a 333cm3
voxel located in the occipital lobe (Fig. 1A and B) due to its
favorable signal to noise proﬁle using a single voxel PRESS
sequence (TR/TE 2000/38 ms, 128 averages, MOIST water
suppression, and 4:52 minutes acquisition time). Additionally, a
spectrum (16 averages) was recorded of unsuppressed water.
For GABA, a MEGA-PRESS sequence (TR/TE=2000/68ms,
320 averages, editing pulses at 1.9 (ON), and 7.46ppm (OFF)
interleaved in 40 blocks, MOIST water suppression, and 10:40
minutes acquisition time) was acquired.[12]
2.3. Data analysis
The metabolite concentrations within the PRESS voxel were
analyzed using the LCModel (linear combination of model
Figure 1. (A) Sagittal and (B) axial view of T1-weighted image of participant without diabetes indicating the 1H-MRS voxel (yellow) in the occipital lobe. (C)
Representative PRESS spectrum (black line) and LCModel ﬁt (red line). The smooth black line shows the estimated baselines by LCModel and the gray line shows
the residuals between the raw data (black line) and the ﬁt (red line). The peaks in the spectrum represent mI, tCho, tCr, Glx, and tNAAmetabolites. (D) Representative
MEGA-PRESS spectrum (black line) and the Gannet ﬁt (red line), yielding GABA+ concentration. The gray line shows the residuals between the raw data and the ﬁt.
van Bussel et al. Medicine (2016) 95:36 www.md-journal.comspectra) software package (version 6.3-1B), which analyzes the
in vivo MR spectra as a linear combination of the spectra of
the individual metabolites.[18] LCModel performs water-scaling
automatically and uses a simulated basis set. The simulated basis
set was provided by Dr Provencher and included the following 16
metabolites: alanine, aspartate, creatine (Cr), GABA, glucose,
Gln, Glu, glycerophosphocholine (GPC), phosphocholine (PCh),
myo-inositol (mI), lactate, NAA, n-acetylaspartylglutamate
(NAAG), scyllo-inositol, taurine, and guanine. Metabolite
estimates were excluded from analysis if the Cramér-Rao lower
bound, an estimate of the error in metabolite quantiﬁcation and
used as reliability indicator, was greater than 15% range. Glu
satisﬁes the requirements of the Cramér–Rao lower bound
<15%. Post hoc analyses were performed for all other
metabolites which fulﬁlled the Cramér-Rao criteria: Glx (the
combined signal of Glu and Gln), mI, total choline (tCho; sum of
GPC and PCh), total NAA (tNAA; sum of NAA andNAAG), and
tCr (sum of Cr and phosphocreatine). Figure 1C shows a typical
spectrum and its best-ﬁt model. In this manuscript, metabolic
concentrations are reported relative to water[19] and expressed
in institutional units (i.u.). To this end, after the in vivo
measurement, the signal from unsuppressed tissue water was
recorded from the same voxel, which served as an endogenous
concentration reference. No corrections for relaxation were
performed.
The GABA concentration (quantiﬁed in i.u. relative to the
unsuppressed water signal from the same volume) was estimated
by analyzing the MEGA-PRESS spectrum using the Gannet 2.0
toolkit, a Matlab-based quantiﬁcation batch analysis tool for
analyzing GABA MEGA-PRESS spectra.[12] A detailed overview
is provided in Edden et al.[12] As the GABA concentration3estimation likely contains contribution frommacromolecules and
homocarnosine, it will therefore be referred to as GABA+.
Figure 1D shows the ﬁtted GABA+ signal. From here on, the
GABA+/H2O ratio is referred to as GABA+ level.
The T1 images were used for the 1H-MRS voxel segmentation
(Fig. 1A and B) to account for differences in tissue composition
whichmay inﬂuence the metabolite concentrations. The 1H-MRS
voxel was coregistered to the T1 image and automatically
segmented as white matter (WM), gray matter (GM), or
cerebrospinal ﬂuid (CSF) using FSL FAST (FMRIB’s Automated
Segmentation Tool, Oxford University, Oxford, UK).[20] Then,
percentages of WM, GM, and CSF in the 1H-MRS voxel were
calculated and the metabolite concentrations were corrected for
CSF content. Furthermore, the ratio of GM to WM in the voxel
was used as a covariate in linear regression analyses.[21]
After careful analyses, data from 41 type 2 diabetes
participants and 39 participants without type 2 diabetes
remained suitable for ﬁnal analysis, as data from 8 participants
were excluded due to claustrophobia (n=2), impaired fasting
blood glucose levels (n=2), parkinsonism (n=1), brain injury
due to an accident (n=1), an incidental ﬁnding (i.e., tumor, n=1),
and unreliable data (n=1). In addition, 1 included participant
had a missing GABA measurement.2.4. Statistical analysis
Descriptive participant characteristics are reported as mean±
standard deviation. Group characteristics were tested using
independent samples t tests and Pearson x2 tests using SPSS
(Statistical Package for Social Sciences, version 20, IBM Corp,
Armonk, NY), with a=0.05.
Table 2
Clinical characteristics of participants with and without type 2
diabetes.
Participants
with type 2
diabetes (n=41)
Participants
without type 2
diabetes (n=39) P value
Type 2 diabetes-related variables
Duration of diabetes, y 9.6±6.7 —
Fasting blood glucose, mmoL/L 7.7±1.6 5.1±0.3 <0.001
HbA1c, % 6.8±0.5 5.6±0.4 <0.001
HbA1c, mmol/mol 50.7±5.6 38.0±4.5 <0.001
Type 2 diabetes medication
None, % 12.2 100 <0.001
∗
Insulin, % 2.4 —
Oral medication, % 75.6 —
Insulin and oral medication, % 9.8 —
Clinical variables
BMI, kg/m2 29.2±3.5 24.7±2.8 <0.001
SBP, mm Hg 152±18 131±18 <0.001
DBP, mm Hg 83±10 76±13 0.012
Cognitive Score
Baseline MMSE total score 28.6±1.4 29.4±0.8 0.006
Repeated MMSE total score 28.7±1.2 29.1±0.9 0.169
Data are mean± standard deviation.
(Baseline/repeated) MMSE= (the Maastricht Study/before MRI) Mini-Mental State Examination. BMI=
body mass index, DBP=diastolic blood pressure, HbA1c=glycated hemoglobin, SBP= systolic blood
pressure. Independent samples t test.
∗
Pearson x2 test.
van Bussel et al. Medicine (2016) 95:36 MedicineLinear regression analyses, adjusted for age, sex, education
level, BMI,[22] and percentage GM/WM ratio were performed to
assess the association of the neurotransmitter concentrations
(GABA+ and Glu) with type 2 diabetes status and cognition
status. Furthermore, the interaction term between type 2 diabetes
and cognition status (lower vs higher cognitive performance) was
added to the linear regression model to investigate the combined
effect of type 2 diabetes and less cognitive performance on
metabolite concentrations.
All analyses were repeated replacing the dichotomous type 2
diabetes status by either fasting blood glucose levels or glycated
hemoglobin (HbA1c), a measure for long-term blood glucose
control. In addition, post hoc analyses were also performed
for other metabolite concentrations (Glx, mI, tCho, tNAA,
and tCr).Table 3
Relationship between the neurotransmitters GABA+ andGluwith type
or HbA1c) and cognitive performance and their corresponding intera
Model 1
Metabolites
Concentration
(i.u.)
Type 2
diabetes status
Cognition
status In
Diabetes Nondiabetes b P b P b
GABA+
∗
1.68±0.45 1.66±0.39 0.626 0.041 0.057 0.800 0.
Glu 11.39±1.15 11.31±1.06 0.311 0.323 0.133 0.572 0.
Concentrations are mean± standard deviation. Standardized b (95% CI) indicates increments/decremen
interaction term represents participants with both type 2 diabetes and less cognitive performance.
GABA+=g-aminobutyric acid, Glu=glutamate, i.u.= institutional units, n=80,
∗
n=79, P=P value.
Model 1=dichotomous type 2 diabetes status, dichotomous cognition status, age, sex, education level
Model 2=model 1 with fasting blood glucose levels instead of the dichotomous type 2 diabetes status
Model 3=model 1 with HbA1c levels instead of the dichotomous type 2 diabetes status.
Note: cognition status is only reported for model 1 because the results did not differ for models 2 and
43. Results
3.1. Characteristics
Table 1 shows the baseline characteristics of the low and high
cognition groups, as participants were selected based on cognitive
performance. The groups were matched on age, sex, education,
and type 2 diabetes status, but score different on cognition.
Table 2 shows the clinical characteristics of participants based on
diabetes status. As expected, participants with type 2 diabetes
had higher fasting blood glucose levels, higher HbA1c levels,
higher BMI, and both higher systolic and diastolic blood pressure
(Table 2). Participants with type 2 diabetes scored signiﬁcantly
worse on baseline MMSE score (P=0.006). Baseline and
repeated MMSE did not differ for all participants (P=0.280).
3.2. 1H-MRS
Linear regression (Table 3) revealed higher GABA+ levels in
participants with type 2 diabetes (P=0.041), but no differences in
Glu concentrations. Linear regression analyses that included the
interaction term (diabetes status  cognition status) revealed no
signiﬁcant interaction.
Additional linear regression analyses replacing type 2 diabetes
status by fasting blood glucose levels or HbA1c showed similar
results (Table 3): higher GABA+ levels in participants with higher
fasting blood glucose levels and in participants with higher
HbA1c levels. Furthermore, linear regression analyses that
included the interaction term (HbA1c levels times cognition
status) revealed higher GABA+ levels in participants with both
higher HbA1c levels and less cognitive performance.
3.3. Post hoc analyses
Post hoc analyses (data not shown) revealed lower tNAA levels in
participants who scored less on cognitive performance (b=0.504,
P=0.030). Other metabolite concentrations did not show
a signiﬁcant analyses with type 2 diabetes or cognitive status
(P>0.267). In addition, higher tCho (b=0.518, P=0.013) levels
were observed in participants with both higher HbA1c levels and
less cognitive performance (interaction analyses).4. Discussion
The current study examined whether neurotransmitter levels are
related to type 2 diabetes, cognitive performance, and the2 diabetes (either dichotomous status, fasting blood glucose levels,
ction term.
Model 2 Model 3
teraction
Fasting blood
glucose Interaction HbA1c Interaction
P b P b P b P b P
661 0.159 0.338 0.016 0.381 0.104 0.316 0.026 0.464 <0.05
077 0.874 0.022 0.880 0.220 0.379 0.013 0.928 0.141 0.575
ts of the metabolites with type 2 diabetes status and cognitive status or the interaction term. The
, BMI, percentage GM/WM ratio in voxel, and interaction between diabetes and cognition status.
.
3.
van Bussel et al. Medicine (2016) 95:36 www.md-journal.compotential interaction between diabetes and cognitive perfor-
mance. The main ﬁndings were that GABA+ is higher in diabetes,
as well as in participants with higher fasting blood glucose levels
and in participants with higher HbA1c levels, that GABA+
concentrations were higher in participants with both higher
HbA1c levels and less cognitive performance. To our knowledge,
this is the ﬁrst study to investigate the role of neurotransmitters in
type 2 diabetes and cognitive decrements.
Higher GABA+ levels were found in participants with type 2
diabetes, in participants with higher fasting blood glucose levels,
and in participants with both higher HbA1c levels and less
cognitive performance. Only one small diabetes study on GABA
1H-MRS is available that reports lower GABA levels in patients
with diabetic neuropathy, although translation of this result to
the current type 2 diabetes population is not straightforward.[14]
In addition, our study population is relatively healthy in terms of
good treatment control according to glucose levels and diabetic
neuropathy is not yet reported in this group. Nevertheless,
increased GABA levels have been found in a type 2 diabetic rat
model.[23] GABAergic inhibition is involved in the control of
many behaviors, such as anxiety, psychosis, aggression, depres-
sion, mood, and cognition.[24] One possible explanation of how
GABA affects cognition is by means of its inhibitory function on
dopamine release in the mesocortical dopamine pathway, which
partly projects to prefrontal cortex. It has previously been
hypothesized that this pathway regulates cognition and executive
functions.[24] Thus, GABA could downregulate the dopamine
activity which might eventually lead to impaired cognitive
performance. This issue cannot be resolved with the results of
the current study, future studies are needed to conﬁrm this
hypothesis.
No signiﬁcant changes in Glu levels were found for participants
with type 2 diabetes, less cognitive performance, nor their
interaction, whereas a previous 1H-MRS study did report
decreased subcortical Glu levels in type 2 diabetes.[13] In contrary
to our participants, these patients were suffering from a major
depression, which could explain the difference in Glu concen-
trations. In addition, an important methodological difference is
that the voxel placement and ﬁeld strength (1.5T) differs
compared with our study. Rather than excluding a potential
role for the glutamatergic neurotransmitter system in less
cognitive performance and type 2 diabetes, it could be the case
that our applied technique for detecting Glu is simply not
sensitive enough. An alternative 1H-MRS technique, making use
of spectral editing, might yield better results, due to an enhanced
sensitivity.[25]
The post hoc analyses revealed signiﬁcant results regarding
tNAA and tCho, and although this study was not designed
speciﬁcally to investigate these metabolites, the results are still
interesting. For participants who scored less on cognitive
performance, we observed lower tNAA levels. tNAA is a
surrogate marker of normal functioning neurons and these
results indicate that a decline in neuronal integrity is associated
with cognitive deﬁcits. Similar results have been found in patients
with mild cognitive impairment, which might suggest that tNAA
could be a predictor for cognitive deﬁcits.[26] With respect to
cognition and type 2 diabetes, one 1H-MRS study observed no
differences inNAAmetabolite concentrations and concluded that
cognitive decline cannot be explained by this metabolite.[27]
Nevertheless, this study was performed at lower ﬁeld strength
(1.5 Tesla), which could make the quantiﬁcation less sensitive to
NAA differences.5Furthermore, our study also observed higher tCho levels in
participants with both higher HbA1c levels and less cognitive
performance. Choline is involved is membrane turnover, which is
a process of loss and replacement of cellular membrane,
inﬂammatory processes, astrocytosis, and in the synthesis of
the neurotransmitter acetylcholine and all these processes could
affect cognitive performance.[24,28] Interestingly, Sahin et al[29]
found higher choline levels in participants with poor glycemic
control. Similar higher choline levels have been found in patients
with Alzheimer Disease characterized by poor recognition
memory performance.[30] Therefore, altered membrane metabo-
lism seems to underlie cognitive decrements both in Alzheimer
Disease and type 2 diabetes, which may indicate a shared
mechanism.
This study has several strengths: ﬁrst, to our knowledge, it is
the ﬁrst study to investigate the neurotransmitter system in
participants with type 2 diabetes in relationship with cognitive
functioning. Second, the participants are extensively character-
ized. Third, the detection and quantiﬁcation of the neuro-
metabolites was applied at higher ﬁeld strength (3T) and using
editing, which results in improved spectral resolution, compared
with 1.5 T in most other studies in type 2 diabetes.
A number of limitations also need to be addressed. First, the
study had a cross-sectional design, so the results should be
interpreted cautiously in terms of causality. Nevertheless, the ﬁrst
results are promising and open directions to future longitudinal
studies assessing neurotransmitter metabolism in type 2 diabetes
and cognitive decrements. Second, our voxel was placed in the
occipital lobe, chosen for optimal spectral quality, rather than
neuropsychological relevance.[4] However, the fact that we do
ﬁnd signiﬁcant effects, despite the occipital placement of the
voxel, might indicate that metabolic effects are global. Future
studies could apply spectroscopic imaging to explore multiple
brain regions to assess whether spatial variations could be related
to speciﬁc cognitive domains. Third, the association between
receptor activity and metabolite concentration is not necessarily
linear but rather intricate. Fourth, as the interaction analyses only
observed an effect with GABA for the continuous HbA1c levels
rather than the dichotomous diabetes status, it seems that HbA1c
levels are more sensitive to detect an interaction effect.4.1. Clinical perspectives
Unfortunately, our study was not able to measure cerebral insulin
levels and therefore we were not able to link whether insulin
causes directly the increase in GABA+ levels. Other studies
already have shown the involvement of insulin on increased
activity of dopamine neurons, and increased expression of the
GABA receptors.[8,9,31] Thus insulin could also indirectly
(independent of GABA+) be involved in the process of cognitive
decrements in participants with type 2 diabetes. Therefore an
important question to be addressed in future studies is whether
insulin modulates directly the levels of GABA+ in the brain of
participants with type 2 diabetes and causes cognitive decre-
ments. Furthermore, our results open directions for future
(longitudinal and pharmacological) studies, which are needed to
unravel the underlying mechanism of cognitive decrements in
type 2 diabetes. It would be interesting to investigate and validate
whether induced changes in the GABAergic system or choline
mechanism, for instance with drug therapies (GABAergic drugs
or choline agonists), can lead to improvements in cognitive
performance or prevention of cognitive deﬁcits in participants
[13] Ajilore O, Haroon E, Kumaran S, et al. Measurement of brain
van Bussel et al. Medicine (2016) 95:36 Medicinewith type 2 diabetes. Interestingly, drug treatment with Xanome-
line, a muscarinic acetylcholine receptor agonist, has already
been shown to provide promising results in improving cognitive
performance in Alzheimer disease, which was reﬂected by the
normalization of cerebral choline to normal levels.[32]
In conclusion, this study revealed alterations in GABAergic
neurotransmitter system in participants with type 2 diabetes,
which were related to lower cognitive functioning.Acknowledgments
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